ISB News

100K Wellness Project Article by Lee Hood and Nathan Price in Clinical Omics

100K Wellness Project article in Clinical Omics written by ISB's Lee Hood and Nathan Price.

The latest press about the 100K Wellness Project is in the May 15 issue of Clinical Omics and features a piece by Dr. Lee Hood, president of Institute for Systems Biology (ISB), and Dr. Nathan Price, ISB’s associate director.

Read “Promoting Wellness and Demystifying Disease: The 100K Project

ISB's 100K Wellness Project featured in Clinical Omics Magazine. The article was written by Dr. Lee Hood and Dr. Nathan Price from Institute for Systems Biology.

ISB’s 100K Wellness Project featured in Clinical Omics Magazine. The article was written by Dr. Lee Hood and Dr. Nathan Price from Institute for Systems Biology.

Recent Articles

  • Timing is Everything: ISB Study Finds Link Between Bowel Movement Frequency and Overall Health

    Everybody poops, but not every day. An ISB-led research team examined the clinical, lifestyle, and multi-omic data of more than 1,400 healthy adults. How often people poop, they found, can have a large influence on one’s physiology and health.

  • Wei Wei, PhD

    Dr. Wei Wei Promoted to Associate Professor

    Wei Wei, PhD – an accomplished cancer researcher with expertise in biotechnology and cancer systems biology – has been promoted to ISB associate professor. The Wei Lab focuses on understanding how cancer cells adapt to therapeutic treatment to foster therapy resistance by coordinating their internal molecular machinery and how these adaptive changes evolve within diverse tumors influenced by the tumor microenvironment. 

  • Drs. Nitin Baliga and James Park

    How Glioblastoma Resists Treatment – and Ways to Prevent It

    Glioblastoma is one of the deadliest and most aggressive forms of primary brain cancer in adults and is known for its ability to resist treatment and to recur. ISB researchers have made breakthrough discoveries in understanding the mechanisms behind acquired resistance, focusing on a rare and stubborn group of cells within tumors called glioma stem-like cells.